Dacomitinib Indications and Basic Drug Overview

Dacomitinib Indications and Basic Drug Overview

Dacomitinib is an oral EGFR tyrosine kinase inhibitor whose core indication is positioned as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with specific gene mutation types.

(1) This drug is indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R substitution mutations as confirmed by an FDA-approved companion diagnostic test. This indication is based on pivotal studies including ARCHER 1050.

(2) Regarding contraindications, the drug label explicitly states "no contraindications," but it must be used prudently in conjunction with all warnings described below.

(3) In clinical practice, priority should be given to confirming the patient's EGFR mutation status and excluding risk factors such as a history of ILD; meanwhile, this first-line indication has received NCCN Category 1 recommendation, establishing it as an important initial treatment option for EGFR-sensitive mutation patients.

Interstitial Lung Disease (ILD) with Dacomitinib

ILD is a serious and potentially fatal adverse event that requires vigilance during dacomitinib treatment, with clearly mandated clinical monitoring and management procedures.

(1) Among 394 patients treated with this drug, the incidence of ILD/pneumonitis was 0.5%, with 0.3% of cases being fatal, indicating that although uncommon, the consequences are severe.

(2) During treatment, respiratory symptoms suggestive of ILD must be closely monitored, including dyspnea, cough, and fever; if any of these symptoms worsen, the drug should be immediately suspended and urgent evaluation (e.g., high-resolution CT) initiated.

(3) If ILD is ultimately confirmed by imaging and clinical assessment, VIZIMPRO must be permanently discontinued; dose reduction or re-administration should not be attempted to avoid recurrence or exacerbation.

Diarrhea and Its Management with Dacomitinib

Diarrhea is one of the most common adverse reactions to dacomitinib, can be severe or fatal, and requires graded management with early intervention.

(1) The overall incidence of diarrhea in patients treated with this drug is 86%, with grade 3 or 4 severe diarrhea occurring in 11% and fatal cases in 0.3%, indicating the need for high vigilance.

(2) For grade 2 or more severe diarrhea, VIZIMPRO should be withheld until symptoms recover to ≤ grade 1; after recovery, treatment may be resumed at the original dose or a reduced dose depending on severity.

(3) Antidiarrheal therapy should be initiated promptly; loperamide or diphenoxylate/atropine combination products are recommended; adequate fluid and electrolyte replacement should also be provided to prevent dehydration and secondary renal injury.